PTC923, Kuvan 100 mg soluble tablets, PTC923 clinical trials

A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin versus Sapropterin in Participants With Phenylketonuria ≥2 years of Age

This study looks at a new medicine called sepiapterin for people aged 18 and over with phenylketonuria (PKU). It compares sepiapterin to an existing medicine, sapropterin, to see how well it lowers levels of a substance called phenylalanine in the blood, which is important for managing PKU.